RMD

ResMed Inc.

September 15, 2026 · intraday

Rarity

1.18

Peak move

+4.98%

Float cap

$31.9B

ResMed is a global medical device and digital health company that designs cloud-connected devices and software for sleep and breathing health. It sells CPAP systems, masks, ventilation and diagnostic products, and care management software to clinicians, home medical equipment providers, and residential care operators. Its products and services help patients, providers, and healthcare systems manage chronic conditions and improve care.

• institutional_flowSep 15 · 04:16 ET

  Corient Private Wealth LP cut its ResMed position by 9.2% in the second quarter, selling 8,507 shares to hold 83,995 shares worth roughly $16.4 million.

  Webmarketbeat.com
• insider_saleSep 15 · 04:16 ET

  ResMed CEO Michael Farrell sold 4,991 shares at $222.44 for $1,110,198.04 on September 8, 2026, and Director Peter C. Farrell sold 970 shares at $234.73 for $227,688.10 on September 2, both under pre-arranged Rule 10b5-1 plans.

  Webmarketbeat.com
• Key eventguidance_changeSep 15

  ResMed gave initial fiscal 2027 guidance at the Morgan Stanley healthcare conference, forecasting 5%-7% core constant-currency revenue growth and 12%-14% core EPS growth, including a $75M Astral field safety notice headwind, with Q1 FY27 gross margin slightly below 62%.

  Webinvesting.comWebde.investing.com
• analyst_ratingSep 15

  RBC Capital analyst Craig Wong-Pan upgraded ResMed to Outperform from Sector Perform and raised the price target to $262 from $244, citing sleep apnea leadership and the React Health Luna G3 recall.

  Webgurufocus.comWebes.investing.comWebtipranks.com
• Key eventexecutive_remarkSep 15

  ResMed CEO Mick Farrell said at the Morgan Stanley 24th Annual Global Healthcare Conference that GLP-1 weight-loss data is a tailwind, potentially adding 50-125 basis points to Americas sleep device growth, while reaffirming low-double-digit annual gross margin improvement through fiscal 2030.

  Webinvesting.com
• spinoff_divestitureSep 15

  ResMed sold its MatrixCare nursing-home software business to Frazier Healthcare Partners for $490 million, exiting the senior-living SaaS market, as disclosed at the Morgan Stanley healthcare conference.

  Webinvesting.comWebde.investing.com
• Key eventproduct_delay_recallSep 15

  ResMed disclosed a $42 million charge tied to the global Astral safety notice and said it will sunset the Astral ventilation platform after 15 years with no new FY2027 sales, shifting resources to AirCurve 11.

  Webde.investing.comWebinvesting.com
• institutional_flowSep 14 · 04:32 ET

  Tidal Investments LLC raised its ResMed stake by 21.1% in the second quarter, acquiring 5,627 additional shares to hold 32,332 shares worth about $6.3 million, per its 13F filing.

  Webmarketbeat.com
• institutional_flowSep 13 · 04:41 ET

  WINTON GROUP Ltd disclosed a new ResMed position of 7,900 shares valued at approximately $1.54 million in its second-quarter 13F filing.

  Webmarketbeat.com
• institutional_flowSep 1 · 05:04 ET

  Public Employees Retirement System of Ohio disclosed a new 50,046-share ResMed position worth approximately $9.75 million, per its second-quarter 13F filing with the SEC.

  Webmarketbeat.com